65,437 trials
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms — -0.81; 4.41; 4.71; 6.69 Percent change — p=<0.001
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint — -4.5; -4.9; -3.8 units on a scale — p=0.201
Elective Cranial Procedures With Dural Incision
Primary: Percentage of Subjects With Surgical Wound Complications, Central Nervous System Events, and Neurosurgical Complications Related to Unplanned Intervention or Return to…
Breast Cancer
Primary: Overall Response Rate (ORR) — 0.489; 0.587 proportion of responders — p=0.117
Hearing Loss
Primary: Temporary Threshold Shift Measurement by Pure Tone Audiometry (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and…
Bipolar Disorder
Primary: Time to Withdrawal From Study — 67.5 days — p=0.010
Influenza
Primary: Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains — 10.4; 10.6; 10.9; 106.1 titre
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 15.5; 11.4; 139.7; 55.8 titer
Low Back Pain
Primary: The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period…
Relapsing Multiple Sclerosis
Primary: Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu-like Symptom Score — 8.5; 9.1 MSTCQ score (units on a scale)
Post Menopausal Women With Early Breast Cancer
Primary: Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores — -5.82…
Diabetes Mellitus, Type 2 · Chronic Renal Insufficiency
Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants
Focal Epilepsy
Primary: Percent of Participants Classified as Responders — 76.7; 80.0 percent of participants — p=<0.0001
Rotavirus · Gastroenteritis
Primary: Number of Participants With Rotavirus Gastroenteritis of Any Severity Caused by Rotavirus Serotypes G1, G2, G3, G4 and G-serotypes Associated With Serotype P1A — 7; 27…
Migraine Headache
Primary: Pain Relief at 2 Hours After Treatment — 223; 238; 18; 129 Participants